More Articles

Insurance payment arrangements are an obstacle to biosimilars use in the US Biosimilars/Research | Posted 04/05/2018

The slow development of the market competition for biosimilars in the US may be caused by several factors, according to Professor Richard Frank from the Department of Health Care Policy, Harvard Me...

FDA rejects trastuzumab and rituximab biosimilars Biosimilars/News | Posted 04/05/2018

US pharma giant Pfizer announced on 23 April 2018 that the US Food and Drug Administration (FDA) had rejected its application for approval of its trastuzumab biosimilar. Then Sandoz, part of Novart...

Challenges in implementing trials to prove interchangeability Reports | Posted 04/05/2018

In the US, a legal framework for approving biosimilars was established in 2009, via the Biologics Price Competition and Innovation Act of 2009 (BPCI Act). As part of the Food and Drug Administratio...

Trends in use of Lipitor after introduction of generic atorvastatin Generics/Research | Posted 04/05/2018

Big savings can be made after the introduction of generics, especially when it comes to high volume categories, such as statins. Pfizer’s Lipitor (atorvastatin) was the best-selling drug of all tim...

Biosimilars in rheumatology: the current state of play Biosimilars/Research | Posted 04/05/2018

Biological disease modifying anti-rheumatic drugs (bDMARDs) have revolutionized the management of rheumatoid arthritis (RA) and other inflammatory diseases. Over two decades, their use has risen ex...

Mylan and Fujifilm Kyowa Kirin Biologics partner on adalimumab biosimilar Pharma News | Posted 04/05/2018

Fujifilm Kyowa Kirin Biologics announced on 11 April 2018 that it will partner with Mylan to commercialize its adalimumab biosimilar FKB327. Mylan will be granted exclusive commercialization rights...

Canadian health committee proposes National Pharmacare programme Policies & Legislation | Posted 04/05/2018

On 19 April 2018, Canada’s Standing Committee on Health released Pharmacare Now: Prescription Medicine Coverage for All Canadians, a report advocating the establishment of a national pharmacare pro...

AbbVie and Samsung Bioepis reach patent deal over Humira biosimilar Biosimilars/General | Posted 04/05/2018

Biosimilars maker Samsung Bioepis announced on 5 April 2018 that it had reached a ‘global resolution’ with pharma giant AbbVie ending all patent litigation regarding AbbVie’s blockbuster arthritis...